Jane Street Group, LLC X4 Pharmaceuticals, Inc Transaction History

Jane Street Group, LLC

$445 Billion
Q3 2024

A detailed history of Jane Street Group, LLC transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Jane Street Group, LLC holds 248,447 shares of XFOR stock, worth $151,552. This represents 0.0% of its overall portfolio holdings.

Number of Shares

248,447

Previous 122,151 103.39%

Holding current value

$151,552

Previous $70,000 137.14%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.54 - $0.86 $68,199 - $108,614	126,296 Added 103.39%	248,447 $166,000
Q2 2024 Aug 14, 2024	BUY	$0.58 - $1.47 $25,925 - $65,707	44,699 Added 57.71%	122,151 $70,000
Q1 2024 May 15, 2024	SELL	$0.72 - $1.46 $37,311 - $75,660	-51,822 Reduced 40.09%	77,452 $107,000
Q4 2023 Feb 14, 2024	BUY	$0.61 - $0.99 $70,703 - $114,747	115,907 Added 867.11%	129,274 $108,000
Q3 2023 Nov 14, 2023	SELL	$1.03 - $2.02 $356,062 - $698,297	-345,692 Reduced 96.28%	13,367 $14,000
Q2 2023 Aug 14, 2023	BUY	$0.82 - $2.49 $276,742 - $840,352	337,491 Added 1564.78%	359,059 $696,000
Q1 2023 May 15, 2023	BUY	$0.8 - $1.22 $17,254 - $26,312	21,568 New	21,568 $18,000
Q2 2022 Aug 16, 2022	SELL	$0.88 - $1.91 $32,425 - $70,377	-36,847 Closed	0 $0
Q1 2022 May 17, 2022	BUY	$1.48 - $2.58 $54,533 - $95,065	36,847 New	36,847 $64,000
Q3 2021 Nov 16, 2021	SELL	$4.53 - $6.45 $324,665 - $462,271	-71,670 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$6.49 - $9.56 $465,138 - $685,165	71,670 New	71,670 $466,000

Others Institutions Holding XFOR

# of Institutions

103

Shares Held

99.9M

Call Options Held

213K

Put Options Held

50.6K

View Full List

About X4 Pharmaceuticals, Inc

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $41.9M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

More about XFOR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC X4 Pharmaceuticals, Inc Transaction History